ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system

Nature Chemical Biology

Volumn 9, Issue 5, 2013, Pages 307-312

  Polier, Sigrun ^a   Samant, Rahul S ^b   Clarke, Paul A ^b   Workman, Paul ^b   Prodromou, Chrisostomos ^a   Pearl, Laurence H ^a  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; B RAF KINASE; CYCLIN DEPENDENT KINASE 4; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; HEAT SHOCK PROTEIN 90; LAPATINIB; SORAFENIB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL DIVISION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE;

ADENOSINE TRIPHOSPHATE; BINDING, COMPETITIVE; CELL CYCLE PROTEINS; CHAPERONINS; HSP90 HEAT-SHOCK PROTEINS; INDOLES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; QUINAZOLINES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84879098944     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1212     Document Type: Article

References (48)

1. Pearl, L.H. & Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 75, 271-294 (2006).
2. Pearl, L.H. Hsp90 and Cdc37-a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 15, 55-61 (2005).
3. Caplan, A.J., Mandal, A.K. & Theodoraki, M.A. Molecular chaperones and protein kinase quality control. Trends Cell Biol. 17, 87-92 (2007).
4. Karnitz, L.M. & Felts, S.J. Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. Sci. STKE 2007, pe22 (2007).
5. Roe, S.M. et al. The mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 116, 87-98 (2004).
6. Vaughan, C.K. et al. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 23, 697-707 (2006).
7. Mimnaugh, E.G., Chavany, C. & Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271, 22796-22801 (1996).
8. Schneider, C. et al. Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90. Proc. Natl. Acad. Sci. USA 93, 14536-14541 (1996).
9. Powers, M.V. & Workman, P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 581, 3758-3769 (2007).
10. Pearl, L.H., Prodromou, C. & Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 410, 439-453 (2008).
11. Makhnevych, T. & Houry, W.A. The role of Hsp90 in protein complex assembly. Biochim. Biophys. Acta 1823, 674-682 (2012).
12. Hunter, T. & Poon, R.Y.C. Cdc37: A protein kinase chaperone? Trends Cell Biol. 7, 157-161 (1997).
13. Terasawa, K. & Minami, Y. A client-binding site of Cdc37. FEBS J. 272, 4684-4690 (2005).
14. Zhao, Q., Boschelli, F., Caplan, A.J. & Arndt, K.T. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. J. Biol. Chem. 279, 12560-12564 (2004).
15. Prince, T. & Matts, R.L. Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. J. Biol. Chem. 279, 39975-39981 (2004).
16. Shao, J., Irwin, A., Hartson, S.D. & Matts, R.L. Functional dissection of cdc37: characterization of domain structure and amino acid residues critical for protein kinase binding. Biochemistry 42, 12577-12588 (2003).
17. Prince, T. & Matts, R.L. Exposure of protein kinase motifs that trigger binding of Hsp90 and Cdc37. Biochem. Biophys. Res. Commun. 338, 1447-1454 (2005).
18. Xu, W. et al. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 12, 120-126 (2005).
19. da Rocha Dias, S. et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65, 10686-10691 (2005).
20. Grbovic, O.M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl. Acad. Sci. USA 103, 57-62 (2006).
21. Tsai, J. et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. USA 105, 3041-3046 (2008).
22. Sharp, S.Y. et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 6, 1198-1211 (2007).
23. Johnson, L.N., Noble, M.E.M. & Owen, D.J. Active and inactive protein kinases: structural basis for regulation. Cell 85, 149-158 (1996).
24. Johnson, L.N. Protein kinase inhibitors: contributions from structure to clinical compounds. Q. Rev. Biophys. 42, 1-40 (2009).
25. Terasawa, K. et al. Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases. Mol. Cell Biol. 26, 3378-3389 (2006).
26. Polier, S., Dragovic, Z., Hartl, F.U. & Bracher, A. Structural basis for the cooperation of Hsp70 and Hsp110 chaperones in protein folding. Cell 133, 1068-1079 (2008).
27. Ni, Q., Shaffer, J. & Adams, J.A. Insights into nucleotide binding in protein kinase A using fluorescent adenosine derivatives. Protein Sci. 9, 1818-1827 (2000).
28. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
29. Joseph, E.W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903-14908 (2010).
30. Miyata, Y. & Nishida, E. CK2 controls multiple protein kinases by phosphorylating a kinase-targeting molecular chaperone, Cdc37. Mol. Cell Biol. 24, 4065-4074 (2004).
31. Zhang, B.H. & Guan, K.L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429-5439 (2000).
32. Wan, P.T. et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116, 855-867 (2004).
33. King, A.J. et al. Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885. Cancer Res. 66, 11100-11105 (2006).
34. Farrell, A. & Morgan, D.O. Cdc37 promotes the stability of protein kinases Cdc28 and Cak1. Mol. Cell Biol. 20, 749-754 (2000).
35. Vaughan, C.K. et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 31, 886-895 (2008).
36. Smith, J.R., Clarke, P.A., de Billy, E. & Workman, P. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene 28, 157-169 (2009).
37. Xu, W. et al. Dynamic tyrosine phosphorylation modulates cycling of the HSP90-P50CDC37-AHA1 chaperone machine. Mol. Cell 47, 434-443 (2012).
38. Taipale, M. et al. Quantitative analysis of hsp90-client interactions reveals principles of substrate recognition. Cell 150, 987-1001 (2012).
39. Nakatani, H. et al. STI571 (Glivec) inhibits the interaction between c-KIT and heat shock protein 90 of the gastrointestinal stromal tumor cell line, GIST-T1. Cancer Sci. 96, 116-119 (2005).
40. Citri, A. et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21, 2407-2417 (2002).
41. Das Thakur, M. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251-255 (2013).
42. Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
43. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596-599 (2010).
44. Smith, J.R. The role of the HSP90 cochaperone CDC37 and its therapeutic potential in cancer. PhD thesis, Univ. London, (2008).
45. Meier, C. et al. Engineering human MEK-1 for structural studies: a case study of combinatorial domain hunting. J. Struct. Biol. 177, 329-334 (2012).
46. Vaughan, C.K., Piper, P.W., Pearl, L.H. & Prodromou, C. A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic HSP90s. FEBS J. 276, 199-209 (2009).
47. cdc37. J. Biol. Chem. 277, 20151-20159 (2002).
48. Holford, J., Sharp, S.Y., Murrer, B.A., Abrams, M. & Kelland, L.R. in vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br. J. Cancer 77, 366-373 (1998).